SREBF1 and cancer: Previous studies have shown that Fatostatin, an inhibitor of SREBP1, can reduce the activity of cancer cells (HeLa, SH-SY5Y, and U2OS) and normal cells (RPE and MEFs), but has a more pronounced effect on cancer cell viability (∼10–20% cell viability vs ∼50–62% cell viability) (Gholkar et al., 2016; Ma et al., 2021).